Atsushi Mizokami

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5097286/publications.pdf

Version: 2024-02-01

117 papers	2,956 citations	201385 27 h-index	197535 49 g-index
120 all docs	120 docs citations	120 times ranked	3742 citing authors

#	Article	IF	Citations
1	Variations in photodynamic diagnosis for bladder cancer due to the quality of endoscopic equipment. Photodiagnosis and Photodynamic Therapy, 2022, 37, 102628.	1.3	4
2	Inhibition of NPC1L1 disrupts adaptive responses of drugâ€tolerant persister cells to chemotherapy. EMBO Molecular Medicine, 2022, 14, e14903.	3.3	46
3	Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice. Anticancer Research, 2022, 42, 1465-1475.	0.5	5
4	Bladder cancer prospective cohort study on highâ€risk nonâ€muscle invasive bladder cancer after photodynamic diagnosisâ€assisted transurethral resection of the bladder tumor (BRIGHT study). International Journal of Urology, 2022, 29, 632-638.	0.5	10
5	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer. Cancers, 2022, 14, 1803.	1.7	5
6	Macrophage Polarity and Disease Control. International Journal of Molecular Sciences, 2022, 23, 144.	1.8	80
7	Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience. Cancer Diagnosis & Prognosis, 2022, 2, 352-359.	0.3	4
8	Impact of Pelvic Anatomical Changes Caused by Radical Prostatectomy. Cancers, 2022, 14, 3050.	1.7	4
9	Androgen receptor signalingâ€targeted therapy and taxane chemotherapy induce visceral metastasis in castrationâ€resistant prostate cancer. Prostate, 2021, 81, 72-80.	1.2	15
10	Threeâ€dimensional structure of seminiferous tubules in the Syrian hamster. Journal of Anatomy, 2021, 238, 86-95.	0.9	9
11	Durable response achieved using Pazopanib for germ tumor cells: A case report. Molecular and Clinical Oncology, 2021, 14, 48.	0.4	2
12	Anti-proliferative and anti-migratory properties of coffee diterpenes kahweol acetate and cafestol in human renal cancer cells. Scientific Reports, 2021, 11, 675.	1.6	16
13	Examination of Necessity for Pelvic Drain Placement After Robot-assisted Radical Prostatectomy. In Vivo, 2021, 35, 2895-2899.	0.6	3
14	Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy. In Vivo, 2021, 35, 1703-1709.	0.6	9
15	Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer. In Vivo, 2021, 35, 1247-1252.	0.6	6
16	A new flavonoid derivative exerts antitumor effects against androgenâ€sensitive to cabazitaxelâ€resistant prostate cancer cells. Prostate, 2021, 81, 295-306.	1.2	7
17	Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer. ACS Omega, 2021, 6, 4842-4849.	1.6	4
18	Testosterone and Bone Health in Men: A Narrative Review. Journal of Clinical Medicine, 2021, 10, 530.	1.0	39

#	Article	IF	Citations
19	Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment. Biomedicines, 2021, 9, 414.	1.4	12
20	Î±-Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer. Molecules, 2021, 26, 2812.	1.7	5
21	Incidence and dosimetric predictive factors of late rectal toxicity after low-dose-rate brachytherapy combined with volumetric modulated arc therapy in high-risk prostate cancer at a single institution: Retrospective study. Brachytherapy, 2021, 20, 584-594.	0.2	1
22	Threeâ€dimensional structure of testis cords in mice and rats. Andrology, 2021, 9, 1911-1922.	1.9	9
23	Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study. International Journal of Urology, 2021, 28, 955-963.	0.5	12
24	Test clamp procedure in robot-assisted partial nephrectomy: is it a safe procedure?. Journal of Robotic Surgery, 2021, , 1.	1.0	0
25	Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 8530.	1.8	50
26	Parenchymal Suture-Assisted Inner Suture Method: Tips to Achieve a Reliable Inner Suture in Partial Nephrectomy. Videourology (New Rochelle, N Y), 2021, 35, .	0.1	0
27	Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer. Cancers, 2021, 13, 4470.	1.7	6
28	The effectiveness of high-dose-rate brachytherapy with external beam radiotherapy for clinically locally advanced and node-positive prostate cancer: long-term results of a retrospective study. International Journal of Clinical Oncology, 2021, 26, 2310-2317.	1.0	2
29	Risk Scoring System for Ra-223 Discontinuation and Its Effect on Prognosis: A Retrospective Study. Cancer Diagnosis & Prognosis, 2021, 1, 323-330.	0.3	2
30	Treatment at an Inexperienced Center Suggests Worse Prognosis of Metastatic Germ Cell Tumors. Cancer Diagnosis & Prognosis, 2021, 1, 13-17.	0.3	0
31	Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study. BMC Cancer, 2021, 21, 1223.	1.1	10
32	Three-dimensional morphological analysis of spermatogenesis in aged mouse testes. Scientific Reports, 2021, 11, 23007.	1.6	5
33	Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer. BMC Cancer, 2021, 21, 1316.	1.1	6
34	Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST.. Urology Journal, 2021, , .	0.3	1
35	Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis. Cancers, 2020, 12, 89.	1.7	33
36	Efficacy of testosterone replacement therapy on pain in hypogonadal men with chronic pain syndrome: A subanalysis of a prospective randomised controlled study in Japan (EARTH study). Andrologia, 2020, 52, e13768.	1.0	11

#	Article	IF	Citations
37	Human papillomavirus 16â€“positive penile Bowenâ€™s disease involving the distal urethra: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2091898.	0.2	0
38	The CCL20-CCR6 Axis in Cancer Progression. International Journal of Molecular Sciences, 2020, 21, 5186.	1.8	124
39	Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity. Japanese Journal of Radiology, 2020, 38, 1197-1208.	1.0	4
40	Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer. Anticancer Research, 2020, 40, 4291-4297.	0.5	5
41	A case of adrenal lymphangioma resected laparoscopically with minimal invasiveness. Urology Case Reports, 2020, 33, 101400.	0.1	2
42	Is the C-C Motif Ligand 2â€“C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?. International Journal of Molecular Sciences, 2020, 21, 9328.	1.8	27
43	Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells. Molecular Cancer Research, 2020, 18, 1290-1301.	1.5	25
44	Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy. Aging Male, 2020, 23, 1210-1216.	0.9	3
45	Three-Dimensional Analysis of Busulfan-Induced Spermatogenesis Disorder in Mice. Frontiers in Cell and Developmental Biology, 2020, 8, 609278.	1.8	10
46	Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review. World Journal of Men?s Health, 2020, 38, 132.	1.7	4
47	CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. Cancer Science, 2019, 110, 279-288.	1.7	40
48	A case of mesh erosion in the ureter eight years after a tension-free vaginal mesh surgery. International Urogynecology Journal, 2019, 30, 2199-2200.	0.7	1
49	Phase I trial of TAKâ€385 in hormone treatmentâ€naÃ¯ve Japanese patients with nonmetastatic prostate cancer. Cancer Medicine, 2019, 8, 5891-5902.	1.3	22
50	Intraoperative hypotension caused by oral administration of 5â€aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. International Journal of Urology, 2019, 26, 1064-1068.	0.5	28
51	Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial. International Journal of Clinical Oncology, 2019, 24, 1629-1631.	1.0	5
52	Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital. Anticancer Research, 2019, 39, 2607-2614.	0.5	9
53	Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy. Anticancer Research, 2019, 39, 2553-2559.	0.5	11
54	Effectiveness of Synthetic Polymer-coated Peripherally Inserted Central Catheter in Patients With Advanced Cancer. In Vivo, 2019, 33, 877-880.	0.6	4

#	Article	IF	Citations
55	Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells. Journal of Clinical Medicine, 2019, 8, 354.	1.0	22
56	Efficacy of combined prophylactic use of levofloxacin and isepamicin for transrectal prostate needle biopsy: A retrospective single-center study. Journal of Infection and Chemotherapy, 2019, 25, 337-340.	0.8	0
57	Novel Prevention Procedure for Inguinal Hernia after Robot-Assisted Radical Prostatectomy: Results from a Prospective Randomized Trial. Journal of Endourology, 2019, 33, 302-308.	1.1	6
58	Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells. Prostate, 2019, 79, 468-479.	1.2	29
59	Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer. Anticancer Research, 2019, 39, 477-486.	0.5	6
60	Câ€€ motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. Cancer Science, 2018, 109, 724-731.	1.7	29
61	Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTATâ€BSI) study. International Journal of Urology, 2018, 25, 492-499.	0.5	8
62	Tumor necrosis factorâ€Î± induces prostate cancer cell migration in lymphatic metastasis through <scp>CCR</scp>7 upregulation. Cancer Science, 2018, 109, 1524-1531.	1.7	72
63	Interleukinâ€6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation. Prostate, 2018, 78, 849-856.	1.2	23
64	Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1). Prostate International, 2018, 6, 7-11.	1.2	7
65	Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2018, 23, 173-180.	1.0	18
66	5â€²-Chloro-2,2â€²-dihydroxychalcone and related flavanoids as treatments for prostate cancer. European Journal of Medicinal Chemistry, 2018, 157, 1143-1152.	2.6	14
67	Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer. Internal Medicine, 2018, 57, 3123-3128.	0.3	9
68	Overexpression of p54nrb/NONO induces differentialEPHA6splicing and contributes to castration-resistant prostate cancer growth. Oncotarget, 2018, 9, 10510-10524.	0.8	22
69	Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway. Oncotarget, 2018, 9, 9206-9218.	0.8	13
70	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget, 2018, 9, 16185-16196.	0.8	26
71	Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. Anticancer Research, 2018, 38, 2045-2055.	0.5	5
72	Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance. Molecular Cancer Research, 2017, 15, 457-466.	1.5	10

#	Article	IF	Citations
73	Therapies for castrationâ€resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. International Journal of Urology, 2017, 24, 566-572.	0.5	22
74	Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer. International Journal of Urology, 2017, 24, 668-673.	0.5	46
75	Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study). Aging Male, 2017, 20, 1-7.	0.9	20
76	Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 2017, 36, 35.	4.9	63
77	Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis. Annals of Nuclear Medicine, 2017, 31, 201-210.	1.2	19
78	Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study. Journal of Pharmaceutical Health Care and Sciences, 2017, 3, 3.	0.4	3
79	Optimal screening interval for men with low baseline prostate-specific antigen levels (â‰¤1.0Ângng/mL) in a prostate cancer screening program. World Journal of Urology, 2017, 35, 579-586.	1.2	1
80	Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis. Oncotarget, 2017, 8, 9739-9751.	0.8	98
81	Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice. Asian Journal of Andrology, 2017, 19, 143.	0.8	23
82	Urinary Obstruction of Transplanted Kidney Caused by Uterine Adenomyosis and 2-Year Posthysterectomy Psoas Abscess in Conjunction with Transplanted Kidney. Case Reports in Transplantation, 2016, 2016, 1-3.	0.1	1
83	Skp2 is associated with paclitaxel resistance in prostate cancer cells. Oncology Reports, 2016, 36, 559-566.	1.2	30
84	Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology, 2016, 49, 838-846.	1.4	74
85	Acute Progression of Recurrent Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer. World Neurosurgery, 2016, 91, 670.e1-670.e6.	0.7	8
86	Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer. World Journal of Urology, 2016, 34, 319-327.	1.2	8
87	Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy. World Journal of Urology, 2016, 34, 261-267.	1.2	18
88	Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. Oncotarget, 2016, 7, 8389-8398.	0.8	34
89	Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma. Anticancer Research, 2016, 36, 4961-4964.	0.5	8
90	Phase II clinical study of radium-223 chloride (BAY 88-8223) in Japanese patients with symptomatic castration-resistant prostate cancer (CRPC) with bone metastases.. Journal of Clinical Oncology, 2016, 34, 167-167.	0.8	0

#	Article	IF	Citations
91	Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report. Journal of Medical Case Reports, 2015, 9, 261.	0.4	0
92	Notch Pathway Inhibition Using PF-03084014, a Î³-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Clinical Cancer Research, 2015, 21, 4619-4629.	3.2	73
93	[14C]Fluciclovine (alias anti-[14C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. Nuclear Medicine and Biology, 2015, 42, 887-892.	0.3	46
94	Reconsideration of progression to CRPC during androgen deprivation therapy. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 164-171.	1.2	24
95	Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute. Anticancer Research, 2015, 35, 1723-8.	0.5	5
96	Primary female urethral adenocarcinoma treated with high dose rate brachytherapy, external beam radiotherapy, and chemotherapy. International Cancer Conference Journal, 2014, 3, 108-111.	0.2	0
97	Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1413-1419.	1.2	35
98	Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (â‰¥2.0 mg/ml). Anticancer Research, 2014, 34, 6739-46.	0.5	8
99	Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Annals of Nuclear Medicine, 2013, 27, 802-807.	1.2	45
100	Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan. International Journal of Clinical Oncology, 2013, 18, 306-313.	1.0	11
101	Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2â€induced STAT3 activation. EMBO Molecular Medicine, 2013, 5, 1383-1401.	3.3	199
102	Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2'-hydroxyflavanone. Anticancer Research, 2013, 33, 4453-61.	0.5	8
103	Heterogenous induction of carcinoma-associated fibroblast-like differentiation in normal human prostatic fibroblasts by co-culturing with prostate cancer cells. Journal of Cellular Biochemistry, 2011, 112, 3604-3611.	1.2	26
104	CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. Prostate, 2010, 70, 48-60.	1.2	24
105	Adrenal androgen levels as predictors of outcome in castrationâ€resistant prostate cancer patients treated with combined androgen blockade using flutamide as a secondâ€line antiâ€androgen. International Journal of Urology, 2010, 17, 337-345.	0.5	26
106	Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. Anticancer Research, 2010, 30, 5201-5.	0.5	23
107	Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocrine-Related Cancer, 2009, 16, 1139-1155.	1.6	59
108	Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor Î²1â€associated osteoblastic changes. Prostate, 2009, 69, 1222-1234.	1.2	45

#	Article	IF	Citations
109	The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate, 2007, 67, 955-967.	1.2	130
110	Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. International Journal of Urology, 2007, 14, 233-239.	0.5	20
111	The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4â€“Induced Invasion in Prostate Cancer. Cancer Research, 2005, 65, 8818-8825.	0.4	62
112	VARIATION IN THE ANTIANDROGENIC ACTIVITY OF DIESEL EXHAUST PARTICULATES EMITTED UNDER DIFFERENT ENGINE LOADS. Polycyclic Aromatic Compounds, 2004, 24, 743-757.	1.4	9
113	The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor. Cancer Research, 2004, 64, 765-771.	0.4	164
114	Long-term exposure of tumor necrosis factor ? causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate, 2001, 46, 319-326.	1.2	19
115	TUMOR NECROSIS FACTOR-Î± REPRESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINE. Journal of Urology, 2000, 164, 800-805.	0.2	80
116	Androgen Receptor: An Overview. Critical Reviews in Eukaryotic Gene Expression, 1995, 5, 97-125.	0.4	260
117	Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. Japanese Journal of Clinical Oncology, 0, , .	0.6	3